Fulltext

Anti-tumor necrosis factor drug survival in axial spondyloarthritis is independent of the classification criteria

Zufferey, Pascal ; Ghosn, Jacqueline ; Becce, Fabio ; Ciurea, Adrian ; Aubry-Rozier, Bérengère ; Finckh, Axel ; So, Alexander

In: Rheumatology International, 2015, vol. 35, no. 2, p. 295-302

Ajouter à la liste personnelle
    Titre
    • Anti-tumor necrosis factor drug survival in axial spondyloarthritis is independent of the classification criteria
    Auteur
    • Zufferey, Pascal. Department of Rheumatology, Lausanne University Hospital, Avenue Pierre-Decker 4, 1011, Lausanne, Switzerland
    • Ghosn, Jacqueline. Department of Rheumatology, Lausanne University Hospital, Avenue Pierre-Decker 4, 1011, Lausanne, Switzerland
    • Becce, Fabio. Department of Diagnostic and Interventional Radiology, Lausanne University Hospital, Lausanne, Switzerland
    • Ciurea, Adrian. Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
    • Aubry-Rozier, Bérengère. Department of Rheumatology, Lausanne University Hospital, Avenue Pierre-Decker 4, 1011, Lausanne, Switzerland
    • Finckh, Axel. Department of Rheumatology, University Hospital Geneva, Geneva, Switzerland
    • So, Alexander. Department of Rheumatology, Lausanne University Hospital, Avenue Pierre-Decker 4, 1011, Lausanne, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Rheumatology International, 2015, vol. 35, no. 2, p. 295-302. Springer Berlin Heidelberg
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:331601
    Summary
    To compare the impact of meeting specific classification criteria [modified New York (mNY), European Spondyloarthropathy Study Group (ESSG), and Assessment of SpondyloArthritis international Society (ASAS) criteria] on anti-tumor necrosis factor (anti-TNF) drug retention, and to determine predictive factors of better drug survival. All patients fulfilling the ESSG criteria for axial spondyloarthritis (SpA) with available data on the axial ASAS and mNY criteria, and who had received at least one anti-TNF treatment were retrospectively retrieved in a single academic institution in Switzerland. Drug retention was computed using survival analysis (Kaplan-Meier), adjusted for potential confounders. Of the 137 patients classified as having axial SpA using the ESSG criteria, 112 also met the ASAS axial SpA criteria, and 77 fulfilled the mNY criteria. Drug retention rates at 12 and 24months for the first biologic therapy were not significantly different between the diagnostic groups. Only the small ASAS non-classified axial SpA group (25 patients) showed a nonsignificant trend toward shorter drug survival. Elevated CRP level, but not the presence of bone marrow edema on magnetic resonance imaging (MRI) scans, was associated with significantly better drug retention (OR 7.9, ICR 4-14). In this cohort, anti-TNF drug survival was independent of the classification criteria. Elevated CRP level, but not positive MRI, was associated with better drug retention.